Clinical trials: Epithelial Neoplasms, Malignant
Non-small Cell Lung Cancer
The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China
This is a multicenter, prospective, longitudinal observational study designed to evaluate the patient-reported outcomes and safety profiles of patients with ALK positive advanced Non-Small Cell Lung Cancer (NSCLC) who received…
- Trial name
- NCT06586801
- Testing
- Patient-reported outcome
- Volunteers
- 800 people
- Sponsor
- Shanghai East Hospital
Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical…
- Conditions
- Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma
- Trial name
- NCT05310305
- Testing
- Radiotherapy for targeted lesions and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
NSCLC Stage IV
Factors Determining the Prognosis in NSCLC Stage IV
This study is a cohort study with patients with advanced NSCLC. Patients will answer questionnaires about symptoms and quality of life and will be submitted to physical and blood tests, and computer tomography.
- Trial name
- LUPROG (NCT04306094)
- Where
- Brazil
- Volunteers
- 217 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Brain Tumor, Central Nervous System Tumor
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00002594
- Testing
- Sargramostim, cyclophosphamide, melphalan
- Where
- 118 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Trial name
- NCT01570166
- Testing
- HR, RFA
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-sen University
Stage III Bladder Cancer, Stage IV Bladder Cancer
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy with that of adjuvant chemotherapy given when the cancer returns in treating patients who have undergone a radical cystectomy for stage…
- Conditions
- Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT00028756
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine sulfate
- Volunteers
- 285 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acral Lentiginous Melanoma, Central Nervous System Melanoma
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease.
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm
- Trial name
- NCT03025256
- Testing
- Biospecimen Collection, Computed Tomography, Lumbar Puncture
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1).
- Trial name
- NCT00113529
- Testing
- Gefitinib + Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Breast Carcinoma
ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers
This study is being done to determine if a clinically available MRI sequence called ZTE imaging better visualizes breast biopsy markers made of bone cement compared to the currently used breast biopsy markers made of metal.
- Trial name
- NCT06873802
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung
ADAM-Afatinib Diarrhea Assessment and Management
This is a non-randomized, open label, two-cohort, multi-institutional study to evaluate the use of diarrheal management tools intended to facilitate timely intervention and treatment modifications due to afatinib…
- Trial name
- NCT01814553
- Testing
- afatinib, loperamide
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04801095
- Testing
- WM-S1-030
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 100 people
- Sponsor
- Wellmarker Bio
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
This phase I trial aims to determine if it is safe to use palliative radiotherapy and lurbinectedin at the same time to treat small cell lung cancer that has spread outside of the chest and that has grown after being treated with…
- Trial name
- NCT05244239
- Testing
- Lurbinectedin, Palliative Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Non Small Cell Lung Cancer
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage…
- Trial name
- NCT03228277
- Testing
- Olmutinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Konkuk University Medical Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer
The purpose of this study is to explore the use of a treatment called interstitial brachytherapy for patients who have a high risk resectable (able to be treated with surgery) recurrent head and neck cancer.
- Trial name
- NCT02794675
- Testing
- Cesium 131
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations.
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Trial name
- NCT01802567
- Testing
- Guided Therapy- Pediatric Gene Analysis Platform
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Giselle Sholler
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Prostate Cancer
Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate
The specific objective of this study is to compare the relative efficacy of the combination of a temporary iridium implant plus external beam irradiation versus standard external beam irradiation alone in patients with Stage B2…
- Trial name
- NCT00548600
- Testing
- Iridium Implant, Standard external beam irradiation
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.